ENHO – Type 2 Diabetes Mellitus

The association between ENHO and type 2 diabetes mellitus is supported by robust clinical findings. A three‑generation family of Chinese origin exhibited T2DM and fatty pancreas features, and a follow‑up study including 19 unrelated patients further reinforced the clinical observation (PMID:28837146). Detailed genetic analysis in these cohorts revealed a specific mutation in ENHO.

Segregation analysis in the family confirmed that the mutation co‑segregated with the disease phenotype in multiple affected members. The mutation, observed in both familial and sporadic cases, underscores the genetic contribution to disease manifestation (PMID:28837146). Such evidence is critical for diagnostic decision‑making in patients exhibiting similar clinical features.

Genetic evidence is further bolstered by the identification of the variant c.167T>G (p.Cys56Trp) in affected individuals. This variant has been reproducibly detected in the three‑generation pedigree as well as in multi‑patient studies, providing a direct molecular link between ENHO alterations and T2DM pathology (PMID:28837146). The recurrence of this variant across unrelated cases adds to its clinical relevance.

Functional studies importantly complement the genetic findings. Experimental evaluation using adropin knockout (AdrKO) mice demonstrated that adropin deficiency leads to impaired glucose homeostasis, reduced endothelial nitric oxide synthase phosphorylation, and loss of regulatory T cells. These animal model data closely mirror the metabolic derangements observed in patients, thus reinforcing the pathogenicity of the ENHO variant (PMID:28837146).

The integration of genetic and functional evidence forms a coherent narrative for the association between ENHO and type 2 diabetes mellitus. The evidence suggests that the c.167T>G (p.Cys56Trp) mutation contributes to disease by affecting metabolic regulation and immune cell balance, which in turn exacerbates the clinical features of T2DM. This integrated approach provides a valuable framework for future diagnostic and therapeutic developments.

Key take‑home sentence: Detailed genetic findings combined with corroborative functional data firmly establish ENHO as a clinically significant contributor to type 2 diabetes mellitus, supporting its use in diagnostic panels and therapeutic target exploration.

References

• Cell death & disease • 2017 • Adropin deficiency worsens HFD-induced metabolic defects PMID:28837146

Evidence Based Scoring (AI generated)